Nektar Data Has Enough for Bulls and Bears as Debate Continues

(Bloomberg) -- A highly-anticipated clinical update from Nektar Therapeutics at a cancer meeting on Friday failed to impress Wall Street, but showed encouraging complete responses in melanoma patie...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.